Trial results · Care handbook
What did people in the trials gain?
Look past the before-and-after promise. Ask who took part, what was measured, what the comparison was, and what happened when treatment ended.
Deep belly fat changed in the main trials.
The main trials involved adults with HIV, the human immunodeficiency virus, and excess belly fat.
They compared tesamorelin with a placebo, a dummy injection without the study medicine.
Falutz’s first large trial
In the published Falutz trial from 2007, 412 adults were studied for 26 weeks.
Deep belly fat fell by 15.2% on tesamorelin and rose by 5.0% on placebo in that paper.
The next large trial
Falutz’s 2010 trial included 404 adults and measured a smaller change.
After 6 months, deep belly fat fell by 10.9% with tesamorelin and by 0.6% with placebo.
For the same first trial, the drug label reports fat falling by 18% with tesamorelin and rising by 2% with placebo. It calculates the changes differently from the paper, so do not mix the two sets of numbers.
The measured result was deep fat around the organs, rather than the number on the scale.
The benefit did not simply stay after treatment ended.
In the main trials, some people stopped tesamorelin after 26 weeks and received a dummy shot instead. Over the next 26 weeks, their deep belly fat returned.
That is a result from those trials, rather than a promise about any one person’s course.
Ask how continued care, the cost of it, and the goal of treatment will be reviewed together. It is a fair part of the decision.
The September 2026 label says long-term effects on the heart and blood vessels are unknown.
An improvement in the measured fat does not answer every question about long-term health.
Plan the cost questionsRead the label’s cautionsOther uses have smaller, different evidence.
A liver-fat trial published in 2019 followed 61 people with HIV for 12 months.
The tesamorelin group lost more liver fat than the placebo group. Treating liver fat was not an approved use in September 2026.
The study was small, involved people with HIV, and called for further work on long-term liver effects.
A 20-week study of 152 adults aged 55 to 87 without HIV found a small improvement on thinking tests, especially tests of planning and managing tasks.
The recorded results do not tell us how much easier daily life became.
A 2025 study of 73 people with HIV compared tesamorelin with usual care for 6 months. It found no clear difference in how much their thinking-test results changed.
Memory treatment and anti-ageing were not approved uses in September 2026.
When a claim reaches beyond the studied group or result, ask what evidence makes that jump reasonable.